RT Journal Article
SR Electronic
T1 Evaluating the health impact, health-system costs and cost-effectiveness of using TrueNat on stool samples compared to usual care for the diagnosis of paediatric tuberculosis in primary care settings: a modelling analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.11.19.24317558
DO 10.1101/2024.11.19.24317558
A1 Mafirakureva, Nyashadzaishe
A1 Daniel, Olugbenga Kayode
A1 Olayinka, Jamiu Olabamiji
A1 Ochei, Kingsley Chinedum
A1 Klinkenberg, Eveline
A1 Ihesie, Austin
A1 Nongo, Debby
A1 Eneogu, Rupert Amanze
A1 Mwansasu, Andwele
A1 Elom, Emeka Uga
A1 Aderonke, Agbaje Vivian
A1 Dakum, Patrick Patrick Sunday
A1 Mensah, Charles Olalekan
A1 Odola, Oluwafemi Christopher
A1 Olayemi, Abiola Oladotun
A1 Faleye, Emily Yemisi
A1 Makinde, Adekunle Omotoso
A1 Dodd, Peter J.
YR 2024
UL http://medrxiv.org/content/early/2024/11/20/2024.11.19.24317558.abstract
AB The World Health Organisation (WHO) recommends rapid molecular diagnostics to improve bacteriological confirmation of tuberculosis in children. TrueNat MTB, MTB Plus and MTB-RIF Dx assays (Molbio Diagnostics, India), recommended by WHO, hold potential as point-of-care tests in resource-limited settings. Using stool samples with these assays could enhance testing access, improve linkage to care, reduce costs, and increase cost-effectiveness over traditional methods. However, evidence on their costs and cost-effectiveness is limited and needed for informed policy decisions on adoption and scale up. We used a decision-tree analytic modelling approach, time-and-motion study, and routine data to estimate the potential impact of implementing stool-based TrueNat testing for the diagnosis of pulmonary tuberculosis in children within Nigerian primary healthcare settings on healthcare outcomes, resource use, health system costs, and cost-effectiveness relative to the standard of care (SoC). The cost per test was $13.06 (standard deviation; $0.77) for TrueNat and $16.25 (standard deviation; $1.34) for Xpert. For every 100 children with presumptive tuberculosis, the stool-based TrueNat testing intervention was projected to increase case detection rate by 29% (95% uncertainty interval [UI 9-48]) and bacteriological confirmation by 6% (95% UI 3-8). Diagnoses at primary health centres (PHC) would increase by 34% (95% UI 20-46), averting 7 (95% UI 2-12) deaths and 182 (95% UI 59-311) discounted DALYs. Although resource use and health system costs increased by $6,172 (95% UI -2,427-10,455) per 100 children, the incremental cost-effectiveness ratio of $34 per DALY averted suggests cost-effectiveness at thresholds of 0.5×GDP per capita. Implementing stool-based TrueNat testing has potential to increase access and reduce direct health system costs associated with the diagnosis of pulmonary tuberculosis in children in routine health care settings. Such an approach is likely to represent a good value for money compared to SoC.Funding USAIDCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis work was made possible through the support of the United States Agency for International Development (USAID), Global Health under the terms of the Infectious Disease Detection and Surveillance contract GS00Q14OADU119. The USAID Nigeria TB team provided technical oversight during the planning and implementation of the study, and in producing the manuscript. Views expressed are not necessarily those of USAID or the United States government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol for the Routine evaluation of stool-based testing to diagnose tuberculosis using the TrueNat platform in comparison to Xpert Ultra on stool in Nigeria (DIGESTER STUDY), which included this economic analysis, was reviewed and approved by the Osun State Health Research Ethical Committee (OSHREC) (REF: OSHREC/PRS/569T/504 dated 05 February 2024) and Oyo State Ministry of Health Research Ethics Committee (HREC) (REF: NHREC/OYOSHRIEC/10/11/22 dated 02 February 2024).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll code and data to reproduce this analysis are publicly available on GitHub https://github.com/nmafirakureva/TruenatModel. https://github.com/nmafirakureva/TruenatModel